Skip to main content

Peer Review reports

From: Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list

Original Submission
21 May 2022 Submitted Original manuscript
15 Jul 2022 Reviewed Reviewer Report - Alexandra Chambers
10 Aug 2022 Reviewed Reviewer Report
31 Aug 2022 Reviewed Reviewer Report
17 Oct 2022 Author responded Author comments - Yingyao Chen
Resubmission - Version 2
17 Oct 2022 Submitted Manuscript version 2
20 Oct 2022 Author responded Author comments - Yingyao Chen
Resubmission - Version 3
20 Oct 2022 Submitted Manuscript version 3
25 Oct 2022 Reviewed Reviewer Report - Alexandra Chambers
14 Nov 2022 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
18 Nov 2022 Editorially accepted
3 Dec 2022 Article published 10.1186/s12913-022-08858-7

You can find further information about peer review here.

Back to article page